Treatment of infants and children with SARS-CoV-2 monoclonal antibodies: a European case series
- Rau, C.
- Auer-Hackenberg, L.
- Deubzer, H.E.
- Schwabel, E.
- Jaros, M.
- Diederichs, A.
- Lehrnbecher, T.
- Holm, M.
- von Linstow, M.L.
- Martin, L.
- Dinges, S.S.
- Rothensteiner, M.
- Siepermann, M.
- Strenger, V.
- von Both, U.
- Teig, N.
- Brinkmann, F.
- Leeb, F.
- Zeitlinger, M.
- Kobbe, R.
- Götzinger, F.
DOIAbstract
BACKGROUND: Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients. METHODS: We retrospectively evaluated mAb treatment in children <12 years of age or <40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries. RESULTS: We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0-13.8, interquartile range (IQR) = 6.2], and median bo...
Add to ORKG